Russian COVID-19 vaccine ready for Indian trial, permission awaited

Russian vaccine Sputnik V is ready for the next phase of clinical trials in India and the Kolkata hospital, which has been picked as the site for the trial, is waiting for the Drug Controller General of India (DCGI) approval, reported PTI.

“If all goes well, Phase-II clinical trials of Russian vaccine Sputnik V will commence at state government-run College of Medicine and Sagore Dutta Hospital by the end of this month”, a senior official of the health department said on Tuesday.

“The necessary surveys, which include visiting the hospital to check its infrastructure and cold storage facilities, have been carried out by a site management organisation before starting the process”, he stated.

Snehendu Koner, head of business development at site management organisation CliniMed LifeSciences, said a report on survey findings has been sent to DCGI for approval.

“We have visited the site, conducted checks on its infrastructure as well as facilities for storing vaccines and immunogenicity samples. We have also gone through the hospital’s records and found it has experiences of conducting clinical trials. Our findings are quite satisfactory and we have sent it to the DCGI for approval,” Koner told PTI when contacted.

Also read:Tourists return to misty Machu Picchu after months of isolation

“Once the DCGI gives green signal, the hospital’s ethics committee will issue a clearance to start the Phase-II clinical trials there, he said “We have also identified the principal investigator as well the co-investigator for the process,” he added.

The clinical trial of Sputnik V, scheduled to be held throughout the country, will be conducted by pharma company Dr Reddy’s Lab, which has joined hands with the Russian Direct Investment Fund (RDIF). According to a health department official, the RDIF will be supplying 100 million doses of its potential COVID-19 vaccine to Dr Reddy’s Lab.

Hundred volunteers will be chosen all over the country, and out of them 75 will be administered the vaccine while 25 others will get a placebo, a substance with no curing properties.